Disappointing Prostate Cancer Phase III Results for Cabozantinib.

Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic,  hormone-resistant (refractory) prostate cancer. The drug continues to be clinically evaluated in metastatic renal cell and advanced hepatocellular carcinomas.

This entry was posted in 2014. Bookmark the permalink.

One Response to Disappointing Prostate Cancer Phase III Results for Cabozantinib.

  1. Molly says:

    I love reading these articles because they’re short but informative.

Leave a Reply

Your email address will not be published. Required fields are marked *